早期AFP应答对经肝动脉化疗栓塞术后中期肝细胞癌患者预后的预测价值

夏冬东; 王恩鑫; 王文军; 白苇; 袁洁; 韩国宏

doi:10.3969/j.issn.1001-5256.2017.06.021

早期AFP应答对经肝动脉化疗栓塞术后中期肝细胞癌患者预后的预测价值

DOI: 10.3969/j.issn.1001-5256.2017.06.021

第四军医大学西京消化病医院消化介入科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2421
- HTML全文浏览量: 13
- PDF下载量: 432
- 被引次数: 1
出版历程
- 出版日期: 2017-06-20

Early alpha-fetoprotein response can predict the prognosis of patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization

摘要

摘要: 目的对AFP应答进行最佳定义并探讨AFP应答与经肝动脉化疗栓塞术（TACE）治疗BCLC-B期肝细胞癌疗效的关系。方法回顾性纳入2010年1月-2014年12月在西京消化病医院消化介入科行TACE治疗连续的中期肝细胞癌患者116例,利用受试者工作特征曲线确定AFP变化率的最佳临界值,将术后AFP降低程度大于临界值的定义为AFP应答（AFP-R）组,其余为AFP不应答（AFP-NR）组。采用Kaplan-Meier法进行生存分析,生存时间的比较采log-rank检验,利用Cox回归进行多因素预后分析。结果中位肿瘤大小为7.5 cm,112例（96.6%）患者的肝功能为Child-Pugh A级。术后1个月AFP较基线降低16%为最佳临界值。AFP-R组的生存明显高于AFP-NR组,中位生存时间分别为26.6（20.932.3）个月和7.0（5.28.8）个月[风险比（HR）=3.56,95%可信区间（95%CI）:2.125.95,P<0.001],在亚组分析中同样能证实AFP-R组的预后明显优于AFPNR组（P值均...
- 癌,肝细胞 /
- 甲胎蛋白类 /
- 化学栓塞,治疗性 /
- 预后
Abstract: Objectives To investigate the best definition of alpha-fetoprotein (AFP) response and its association with the outcome of patients with BCLC stage B hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) . Methods A retrospective analysis was performed for the clinical data of 116 patients with intermediate-stage HCC who were treated with TACE in Department of Liver Disease and Digestive Interventional Radiology in Xijing Hospital of Digestive Disease from January 2010 to December 2014. The receiver operating characteristic curve was used to determine the optimal cut-off value of AFP change rate. The patients with a reduction in AFP greater than the cut-off value after surgery were defined as AFP response group (AFP-R group) , and the other patients were defined as AFP non-response group (AFP-NR group) . The Cox regression model was used for multivariate prognostic analyses. Results The median tumor size was 7. 5 cm, and of all patients, 112 (96. 6%) had Child-Pugh class A liver function. The optimal cut-off value was defined as a 16% reduction in AFP at 1 month after surgery, compared with baseline. The AFP-R group had a significantly longer median survival time than the AFP-NR group (26. 6 (20. 9-32. 3) months vs 7. 0 (5. 2-8. 8) months, HR = 3. 56, 95% CI: 2. 12-5. 95, P <0. 001) . The sub-group analysis showed that the AFP-NR group had significantly better prognosis than the AFP-NR group (P < 0. 05) .The multivariate analysis showed that age (HR = 0. 97, 95% CI: 0. 95-0. 99, P = 0. 003) , tumor size (HR = 1. 14, 95% CI: 1. 06-1. 22, P < 0. 001) , Eastern Cooperative Oncology Group performance score (HR = 2. 15, 95% CI: 1. 24-3. 73, P = 0. 006) , and AFP response (HR = 1. 56, 95% CI: 2. 12-5. 95, P < 0. 001) were independent risk factors for patients' survival. Conclusion Early AFP response can predict the prognosis of patients with intermediate-stage HCC treated with TACE.
- carcinoma, hepatocellular /
- alpha-fetoproteins /
- chemoembolization /
- therapeutic

HTML全文

参考文献(24)

[1]JEMAL A, BRAY F, CENTER MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61 (2) :69-90.

[2]BOLONDI L, BURROUGHS A, DUFOUR JF, et al.Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma:proposal for a subclassification to facilitate treatment decisions[J].Semin Liver Dis, 2012, 32 (4) :348-359.

[3]BRUIX J, SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology, 2011, 53 (3) :1020-1022.

[4]European Association for the Study of the Liver;European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].J Hepatol, 2012, 56 (4) :908-943.

[5]HEIMBACH J, KULIK LM, FINN R, et al.AASLD guidelines for the treatment of hepatocellular carcinoma[J].Hepatology, 2017.[Epub ahead of print]

[6]PARK JW, CHEN M, COLOMBO M, et al.Global patterns of hepatocellular carcinoma management from diagnosis to death:the BRIDGE Study[J].Liver Int, 2015, 35 (9) :2155-2166.

[7]TREVISANI F, D'INTINO PE, MORSELLI-LABATE AM, et al.Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease:influence of HBs Ag and anti-HCV status[J].J Hepatol, 2001, 34 (4) :570-575.

[8]MARRERO JA, FENG Z, WANG Y, et al.Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma[J].Gastroenterology, 2009, 137 (1) :110-118.

[9]NOMURA F, OHNISHI K, TANABE Y.Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels.Analysis of 606 patients[J].Cancer, 1989, 64 (8) :1700-1707.

[10]IZUMI R, SHIMIZU K, KIRIYAMA M, et al.Alpha-fetoprotein production by hepatocellular carcinoma is prognostic of poor patient survival[J].J Surg Oncol, 1992, 49 (3) :151-155.

[11]PENG SY, CHEN WJ, LAI PL, et al.High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma:significance of hepatitis virus infection, age, p53 and beta-catenin mutations[J].Int J Cancer, 2004, 112 (1) :44-50.

[12]LEE YK, KIM SU, KIM DY, et al.Prognostic value of alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization[J].BMC Cancer, 2013, 13:5.

[13]MEMON K, KULIK L, LEWANDOWSKI RJ, et al.Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies:a subgroup analysis[J].J Hepatol, 2012, 56 (5) :1112-1120.

[14]RIAZ A, RYU RK, KULIK LM, et al.Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma:oncologic marker of radiologic response, progression, and survival[J].J Clin Oncol, 2009, 27 (34) :5734-5742.

[15]PARK WH, SHIM JH, HAN SB, et al.Clinical utility of desgamma-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J].J Vasc Interv Radiol, 2012, 23 (7) :927-936.

[16]PERSONENI N, BOZZARELLI S, PRESSIANI T, et al.Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma[J].J Hepatol, 2012, 57 (1) :101-107.

[17]LO CM, NGAN H, TSO WK, et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology, 2002, 35 (5) :1164-1171.

[18]LLOVET JM, REAL MI, MONTANA X, et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet, 2002, 359 (9319) :1734-1739.

[19]FORNER A, GILABERT M, BRUIX J, et al.Treatment of intermediate-stage hepatocellular carcinoma[J].Nat Rev Clin Oncol, 2014, 11 (9) :525-535.

[20]RAOUL JL, SANGRO B, FORNER A, et al.Evolving strategies for the management of intermediate-stage hepatocellular carcinoma:available evidence and expert opinion on the use of transarterial chemoembolization[J].Cancer Treat Rev, 2011, 37 (3) :212-220.

[21]BRUIX J, REIG M, RIMOLA J, et al.Clinical decision making and research in hepatocellular carcinoma:pivotal role of imaging techniques[J].Hepatology, 2011, 54 (6) :2238-2244.

[22]BRUIX J, REIG M, SHERMAN M.Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J].Gastroenterology, 2016, 150 (4) :835-853.

[23]JIA J, QI XS, HAN GH.Prognostic value ofα-fetoprotein response in treatment of hepatocellular carcinoma[J].J Clin Hepatol, 2013, 28 (8) :576-580. (in Chinese) 贾佳, 祁兴顺, 韩国宏.甲胎蛋白应答在肝细胞癌治疗中的预后价值[J].临床肝胆病杂志, 2013, 28 (8) :576-580.

[24]LIU L, ZHAO Y, JIA J, et al.The prognostic value of alpha-fetoprotein response for advanced-stage hepatocellular carcinoma treated with sorafenib combined with transarterial chemoembolization[J].Sci Rep, 2016, 6:19851.

施引文献